Sam Brusco, Associate Editor10.25.22
BioSig Technologies will sponsor a research agreement with Cleveland Clinic Foundation (CCF) to investigate further clinical applications for intracardiac signals gathered by its PURE EP system.
Cleveland Clinic will begin by undergo physician-initiated research investigating PURE EP’s potential to tackle common limitations of signal processing and signal use expansion for electrophysiology ablation procedures. Further applications are likely to come.
“As a non-profit, research, education, and healthcare institution, Cleveland Clinic has a long legacy of innovation in cardiovascular disease, and specifically in the field of electrophysiology. At BioSig, we embody their commitment to clinical discovery and ensuring that optimal treatments are made available to patients with efficiency and efficacy,” Gray Fleming, BioSig’s chief commercialization officer told the press. “We are honored to align ourselves with Cleveland Clinic’s expertise as we discover new ways to positively impact procedural workflows by leveraging digital signal processing technology.”
BioSig’s PURE EP System is currently under evaluation at both Main and Fairview campuses of Cleveland Clinic’s Heart, Vascular & Thoracic Institute.
Cleveland Clinic will begin by undergo physician-initiated research investigating PURE EP’s potential to tackle common limitations of signal processing and signal use expansion for electrophysiology ablation procedures. Further applications are likely to come.
“As a non-profit, research, education, and healthcare institution, Cleveland Clinic has a long legacy of innovation in cardiovascular disease, and specifically in the field of electrophysiology. At BioSig, we embody their commitment to clinical discovery and ensuring that optimal treatments are made available to patients with efficiency and efficacy,” Gray Fleming, BioSig’s chief commercialization officer told the press. “We are honored to align ourselves with Cleveland Clinic’s expertise as we discover new ways to positively impact procedural workflows by leveraging digital signal processing technology.”
BioSig’s PURE EP System is currently under evaluation at both Main and Fairview campuses of Cleveland Clinic’s Heart, Vascular & Thoracic Institute.